Cover Image

The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis

Purpose of this single-centre retrospective study was to assess the outcome of allogeneic hematopoietic cell transplantation (alloHCT) for relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL) by intent-to-transplant (ITT). Included were all consecutive patients with diffuse large B-cell lymphoma (DL...

Full description

Saved in:
Bibliographic Details
Main Authors: Selberg, Lorenz (Author) , Stadtherr, Peter (Author) , Dietrich, Sascha (Author) , Tran, Thuong Hien (Author) , Luft, Thomas (Author) , Hegenbart, Ute (Author) , Bondong, Andrea (Author) , Meißner, Julia (Author) , Liebers, Nora (Author) , Schmitt, Michael (Author) , Ho, Anthony Dick (Author) , Müller-Tidow, Carsten (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: 2021
In: Bone marrow transplantation
Year: 2021, Volume: 56, Issue: 1, Pages: 30-37
ISSN:1476-5365
DOI:10.1038/s41409-020-0976-4
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41409-020-0976-4
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41409-020-0976-4
Get full text
Author Notes:Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, T. Hien Tran, Thomas Luft, Ute Hegenbart, Andrea Bondong, Julia Meissner, Nora Liebers, Michael Schmitt, Anthony Dick Ho, Carsten Müller-Tidow, Peter Dreger
Description
Summary:Purpose of this single-centre retrospective study was to assess the outcome of allogeneic hematopoietic cell transplantation (alloHCT) for relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL) by intent-to-transplant (ITT). Included were all consecutive patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and peripheral T-cell lymphoma (PTCL) for whom a donor search was performed between 2004 and 2018. Primary endpoint was overall survival (OS) measured from search initiation. A donor search was initiated for 189 patients (DLBCL 61, FL 32, MCL 43, and PTCL 53), with 76% of the patients having active disease. OS at 5 years after search initiation for DLBCL, FL, MCL, and PTCL was 26%, 44%, 52%, and 50%, respectively. AlloHCT was performed in 137 patients (72%; DLBCL 64%). Main reason for not undergoing alloHCT was disease progression, whereas donor unavailability accounted for only 4% of pretransplantation failures. These results suggest that survival of patients with r/r NHL entering the alloHCT route may be overestimated by a factor of 1.2-1.4 if based on actually transplanted patients only. This effect should be taken into account when using alloHCT as benchmark for new therapeutic approaches for the treatment of poor-risk NHL.
Item Description:Published online: 18 June 2020
Gesehen am 07.09.2021
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/s41409-020-0976-4

Similar Items